会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Biphenyl vasopressin agonists
    • 联苯加压素激动剂
    • US20050075328A1
    • 2005-04-07
    • US10980939
    • 2004-11-04
    • Amedeo FailliJohn DuszaThomas CaggianoJay ShumskyKevin MemoliEugene Trybulski
    • Amedeo FailliJohn DuszaThomas CaggianoJay ShumskyKevin MemoliEugene Trybulski
    • A61K31/55A61K31/551A61K31/5513A61K31/5517A61P5/02A61P13/00A61P13/02C07D243/10C07D243/38C07D401/06C07D471/04C07D471/14C07D487/04C07D495/04C07D487/12
    • C07D243/10C07D243/38C07D401/06C07D471/04C07D471/14C07D487/04C07D495/04
    • A compound of the formulae (I) or (II): wherein: Y is a moiety selected from NR or —(CH2)n; wherein R is hydrogen or (C1-C6) lower alkyl, and n is 1; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C1-C6) lower alkyl, halogen, cyano, CF3, hydroxy, (C1-C6) lower alkoxy, (C1-C6) lower alkoxy carbonyl, carboxy, —CONH2, —CONH[(C1-C6) lower alkyl], —CON[(C1-C6) lower alkyl]2; or (2) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, halogen or (C1-C6) lower alkoxy; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C1-C6) lower alkyl, halogen, cyano, CF3, hydroxy, (C1-C6) lower alkoxy, or (C1-C6) lower alkoxy carbonyl, carboxy, —CONH2, —CONH[(C1-C6) lower alkyl], —CON[(C1-C6) lower alkyl]2; or (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, (C1-C6) lower alkoxy, or halogen; or (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, halogen, or (C1-C6) lower alkoxy; represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur atom, optionally substituted by (C1-C6) lower alkyl, halogen, or (C1-C6) lower alkoxy; R1 is a moiety of the formula and R2, R3, R7, R8 and R9 are, independently, selected from a group consisting of hydrogen, (C1-C3) lower alkyl, OCH3, halogen, CF3, —SCH3, OCF3, SCF3, or CN; or a pharmaceutically acceptable salt, or pro-drug form thereof.
    • 式(I)或(II)的化合物:其中:Y是选自NR或 - (CH 2)n的部分; 其中R是氢或(C1-C6)低级烷基,n是1; (C1-C6)低级烷基,卤素,氰基,CF3,羟基,(C1-C6)低级烷氧基,(C1-C6)低级烷氧基,(C1-C6)低级烷氧基,(C1-C6) C 1 -C 6低级烷氧基羰基,羧基-CONH 2,-CONH [(C 1 -C 6)低级烷基],-CON [(C 1 -C 6)低级烷基] 或(2)任选被(C 1 -C 6)低级烷基,卤素或(C 1 -C 6)低级烷氧基取代的具有一个氮原子的6元芳族(不饱和)杂环; 表示:(1)任选被一个或两个取代基取代的苯环,所述取代基独立地选自氢,(C 1 -C 6)低级烷基,卤素,氰基,CF 3,羟基,(C 1 -C 6)低级烷氧基或 (C 1 -C 6)低级烷氧基羰基,羧基,-CONH 2,-CONH [(C 1 -C 6)低级烷基],-CON [(C 1 -C 6)低级烷基] 或(2)任选被(C 1 -C 6)低级烷基,(C 1 -C 6)低级烷氧基或卤素取代的具有一个氮原子的5元芳族(不饱和)杂环; 或(3)具有一个氮原子,任选被(C 1 -C 6)低级烷基,卤素或(C 1 -C 6)低级烷氧基取代的6元芳族(不饱和)杂环; 表示任选被(C 1 -C 6)低级烷基,卤素或(C 1 -C 6)低级烷氧基取代的具有一个硫原子的5元芳族(不饱和)杂环; R 1是下式的部分,R 2,R 3,R 7,R 8和R 9独立地选自氢
    • 7. 发明申请
    • Biphenyl vasopressin agonists
    • US20060276456A1
    • 2006-12-07
    • US11502982
    • 2006-08-11
    • Kevin MemoliAmedeo FailliThomas CaggianoJay ShumskyEugene TrybulskiJohn Dusza
    • Kevin MemoliAmedeo FailliThomas CaggianoJay ShumskyEugene TrybulskiJohn Dusza
    • A61K31/551C07D487/02
    • C07D243/10C07D243/38C07D401/06C07D471/04C07D471/14C07D487/04C07D495/04
    • A compound of the formulae (I) or (II): wherein: Y is a moiety selected from NR or —(CH2)n; wherein R is hydrogen or (C1-C6) lower alkyl, and n is 1; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C1-C6) lower alkyl, halogen, cyano, CF3, hydroxy, (C1-C6) lower alkoxy, (C1-C6) lower alkoxy carbonyl, carboxy, —CONH2, —CONH[(C1-C6) lower alkyl], —CON[(C1-C6) lower alkyl]2; or (2) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, halogen or (C1-C6) lower alkoxy; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C1-C6) lower alkyl, halogen, cyano, CF3, hydroxy, (C1-C6) lower alkoxy, or (C1-C6) lower alkoxy carbonyl, carboxy, —CONH2, —CONH[(C1-C6) lower alkyl], —CON[(C1-C6) lower alkyl]2; or (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, (C1-C6) lower alkoxy, or halogen; or (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, halogen, or (C1-C6) lower alkoxy; represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur atom, optionally substituted by (C1-C6) lower alkyl, halogen, or (C1-C6) lower alkoxy; R1 is a moiety of the formula and R2, R3, R7, R8 and R9 are, independently, selected from a group consisting of hydrogen, (C1-C3) lower alkyl, OCH3, halogen, CF3, —SCH3, OCF3, SCF3, or CN; or a pharmaceutically acceptable salt, or pro-drug form thereof.